In Vivo Pharmacokinetics & Bioanalysis

Understanding how a drug behaves in the body is essential to progressing compounds through the drug discovery pipeline. At Sygnature Discovery, our combined in vivo pharmacokinetic (PK) and bioanalysis services provide critical insight into a compound’s absorption, distribution, metabolism, and excretion (ADME). By integrating expertly designed rodent PK studies with high-sensitivity bioanalytical quantification, we help researchers evaluate systemic exposure, support dosing strategies, and predict clinical performance. From tailored non-GLP study design to advanced UPLC-MS/MS analysis, our end-to-end platform ensures accurate, timely data to drive decision-making in preclinical development.

The Importance of in vivo Pharmacokinetic Services

In vivo pharmacokinetic studies are vital for understanding how a drug is absorbed, distributed, metabolized, and excreted in a living organism. These studies provide quantitative data on key parameters such as half-life, bioavailability, clearance rate, and volume of distribution—insights that inform early safety and efficacy assessments.

Sygnature Discovery’s in vivo pharmacokinetic services are tailored for preclinical studies in rodent models. Whether administered intravenously, orally, or subcutaneously, compounds are evaluated using scientifically robust protocols to generate high-quality PK profiles. Our in-house in vivo pharmacologists ensure every study is customised to meet specific program needs, providing the agility required in early-stage development.

Integrated in vivo PK Support at Sygnature Discovery

Sygnature Discovery offers fully integrated in vivo pharmacokinetic services as part of our broader discovery platform, combining in vivo pharmacology, bioanalysis, and formulation science. This cohesive approach provides:

• Non-GLP rodent PK studies
• Study design and project planning
• Flexible dosing routes (IV, PO, SC)
• Sample collection and processing
• UPLC-MS/MS
• Expert data interpretation and reporting

Sygnature Discovery’s Form & Formulation team supports compound optimisation for improved solubility and systemic exposure, ensuring PK studies reflect real-world drug delivery conditions.

Bioanalysis Services for Preclinical Drug Discovery

The Role of Bioanalysis PK and ADME Studies

Accurate quantification of drug concentrations in biological matrices is essential for understanding a compound’s pharmacokinetics and therapeutic potential. Sygnature Discovery’s bioanalysis services provide high-sensitivity, high-specificity measurements of parent compounds, metabolites and biomarkers in plasma, blood, urine and tissue samples.

Our state-of-the-art bioanalytical platform enables:

• PK and ADME profiling
• Exposure-response assessments
• Metabolite identification
• Dose linearity evaluations
• Biomarker quantification

Our scientists provide rigorous scientific oversight for all services, ensuring robust, reproducible results that accelerate preclinical decision-making.

High-Resolution, High-Throughput Bioanalysis

Sygnature Discovery employs ultra-performance liquid chromatography (UPLC) coupled with tandem mass spectrometry (MS/MS) to deliver both high sensitivity and efficient throughput. As a result, this advanced analytical platform enables the reliable detection and quantification of diverse compound classes. Specifically, we support the analysis of:

• Traditional drug-like small molecules
• Peptides and other larger analytes
• Highly polar compounds through hydrophilic interaction liquid chromatography (HILC)

These capabilities enable us to offer a rapid turnaround on bioanalysis studies. At the same time, we maintain the high specificity and accuracy required to generate regulatory-compliant data packages, ensuring that your development program remains on track and fully supported by robust bioanalytical data.

Why Choose Sygnature Discovery?

Sygnature Discovery delivers comprehensive, high-quality in vivo pharmacokinetic and bioanalysis services that support confident, data-driven decisions in early drug development. We combine scientific expertise, state-of-the-art instrumentation and a fully integrated drug discovery infrastructure to:

• Guide compound selection with early PK insights
• Quantify systemic drug exposure with precision
• Support formulation strategies with real-world relevance
• Enable fast, flexible non-GLP study execution

Our scientists act as an extension of your discovery team, tailoring studies to your objectives and timelines.